TRT: Products - OrthoGold 280

The OrthoGold 280 is TRT’s flagship device; a high-end system for orthopedic shockwave therapy. Developed for use in sports medicine and traumatology, the OrthoGold 280 is designed to effectively treat a broad range of injuries. Its proven technology is backed by extensive research in areas such as tendonopathies and bone pathologies.

Great penetration depth ensures successful treatment even for acute and hard-to-treat injuries. The OrthoGold 280 is suitable for both low and high-energy treatments such as:

Pseudarthrosis and Delayed-union Fractures
OCD (Osteochondritis Dissecans)
Chronic Lateral Epicondylitis
Plantar Fasciitis
Patella Tendon Syndrome
Achillodynia
Hip Necrosis

and provides a particularly economical solution for high volume facilities.

2008 FDA Filing!

In December 2008 TRT filed its application for Pre-Market Approval (PMA) of OrthoGold 280 indicated for use in treatment of atrophic tibia non-union fractures. TRT will provide further updates during the FDA review process as they become available.

This device is not approved for marketing, distribution or use in the United States.





	OrthoGold 280™ The OrthoGold 280 is TRT’s flagship device; a high-end system for orthopedic shockwave therapy. Developed for use in sports medicine and traumatology, the OrthoGold 280 is designed to effectively treat a broad range of injuries. Its proven technology is backed by extensive research in areas such as tendonopathies and bone pathologies. Great penetration depth ensures successful treatment even for acute and hard-to-treat injuries. The OrthoGold 280 is suitable for both low and high-energy treatments such as: Pseudarthrosis and Delayed-union Fractures OCD (Osteochondritis Dissecans) Chronic Lateral Epicondylitis Plantar Fasciitis Patella Tendon Syndrome Achillodynia Hip Necrosis and provides a particularly economical solution for high volume facilities. 2008 FDA Filing! In December 2008 TRT filed its application for Pre-Market Approval (PMA) of OrthoGold 280 indicated for use in treatment of atrophic tibia non-union fractures. TRT will provide further updates during the FDA review process as they become available. This device is not approved for marketing, distribution or use in the United States.